Orlando, Fla.—In a double-blind, phase 3 trial in patients with Crohn’s disease, stem cell treatment of perianal fistulas provided even better outcomes at 52 weeks than originally reported at 26 weeks. In Europe, where the trial was conducted, approval of the therapy, called Cx601 cells, is expected imminently.
“There is still a lot to learn, but I think these cells are a revolutionary step forward compared to what we have today,” said Daniel C. Baumgart, MD, PhD, of the